Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of Ranibizumab in
patients with Clinically Significant Diabetic Macular Edema (CSDME). It will also compare
treatment outcomes for patients receiving 0.5mg Ranibizumab and higher doses of 1.0mg and
2.0mg Ranibizumab.